Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- PHARMACEUTICALS18(5) · #748 · 2025
- 피인용
- Web of Science 0Scopus 0
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2024 4.8
- ISSN
- 1424-8247
저자
- Yang, Sung-yoon제1저자Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
- Ngo, Lien ThiPHENIKAA Univ, Fac Pharm, Hanoi 12116, Vietnam
- Lee, SoyoungChungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
- Yun, Hwi-yeolChungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
- Bui, Tham ThiChungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
- 김동현Pusan Natl Univ, Korean Med Hosp, Dept Internal Med, Yangsan 50612, South Korea
- Chae, Jung-woo교신저자Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
- 박소정교신저자Pusan Natl Univ, Korean Med Hosp, Dept Internal Med, Yangsan 50612, South Korea
초록
Objectives: HangAmDan-B1 (HAD-B1), a blended herbal mixture, has been investigated as an adjuvant therapy with afatinib (AFT) to treat non-small lung cancer (NSCLC). Although preclinical studies demonstrated promising synergistic results, clinical trials have not yet confirmed the expected benefits. This study aims to quantitatively examine the exposure-response relationship and synergistic interactions through pharmacokinetic/pharmacodynamic (PK/PD) modeling. Methods: A PK/PD model was established and validated based on tumor growth profiles from a xenograft mouse study of gefitinib-resistant HCC827. Model-based simulations were performed to predict and assess therapeutic effects across different treatment groups. Results: The PK/PD model confirmed HAD-B1 enhances the potency of AFT by 1.45-fold. Model-based simulations predicted that combination treatment maintains a lower tumor size compared to AFT monotherapy. Conclusions: This study quantitatively demonstrated the synergistic interaction between HAD-B1 and AFT. The developed PK/PD model provides insights into potential dosing strategies to treat NSCLC resistant to EGFR-TKIs. Further clinical trials are warranted to validate these findings and refine dosing strategies to improve therapeutic outcomes.
키워드
pharmacokinetic/pharmacodynamic modelingafatinibhangamdan-B1non-small cell lung cancerEGFR-TKI resistancedrug-drug interactionsCELL LUNG-CANCEREGFR-TKIPHARMACOKINETICS
식별자
- Scopus EID
- 2-s2.0-105006722731
- WoS UID
- 001495716800001



로그인
연구물 목록으로